Ropinirole: current status of the studies.
Ropinirole is a modern, non-ergoline dopamine agonist which has been shown to be effective as monotherapy as well as combination therapy against idiopathic Parkinson's disease. In addition to improving bradykinesia, rigor and tremor, it will ameliorate the abilities of daily living as well as depressive mood. The long-term complications of L-dopa are diminished and the existing complications are reduced. A neuroprotective effect is under discussion. In addition to Parkinson's disease, ropinirole is also used successfully in the treatment of restless legs syndrome.
Jost
Wolfgang H
WH
Dept. of Neurology, Deutsche Klinik für Diagnostik, Aukammallee 33, 65191 Wiesbaden, Germany. jost.neuro@dkd-wiesbaden.de
D001971:Bromocriptine / Q000009:adverse effects; D018491:Dopamine Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D007980:Levodopa / Q000009:adverse effects; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology
D018491:Dopamine Agonists; D007211:Indoles; D018696:Neuroprotective Agents; C046649:ropinirole; D001971:Bromocriptine; D007980:Levodopa